BeOne Medicines (49BA) Q3 2026 Earnings Report

The call was strongly positive, characterized by 33% product revenue growth, substantially higher operating income and free cash flow, raised 2026 guidance, sustained BRUKINSA momentum, and broad progress across hematology and solid tumor programs. The main challenges were the approximately $50 million order-timing benefit, future revenue pressure from biosimilars and potential VBP inclusion, a statutory Medicare Part D headwind, a PHESGO impairment charge, a more modest pace of future margin expansion, and the delayed tacabrutideg filing. Highlights significantly outweighed lowlights.

For 2026, BeOne Medicines raised and narrowed guidance to total revenue of $6.9 billion-$7 billion, gross margin in the high 80% range, operating expenses of $4.9 billion-$5 billion, GAAP operating income of $1.2 billion-$1.3 billion, and non-GAAP operating income of $1.9 billion-$2 billion; it expects a modest net pricing benefit in the U.S. for BRUKINSA for the balance of the year, while looking ahead to 2027, it expects relatively stable net pricing and a flat to modest headwind from the increase in Medicare Part D manufacturer liability, operating expenses growth to be at least consistent with where we have been over the past several years, operating income to continue to grow meaningfully, and the pace of margin expansion to be modest as compared to 2025 and 2026; the current expectation is that the income tax valuation allowance reversal will occur in the fourth quarter and result in a material tax benefit.